{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:08:08Z","timestamp":1791331688031,"version":"4.3.1"},"reference-count":48,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Cefepime-enmetazobactam is a novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination showing good activity against multidrug-resistant (MDR) Gram-negative bacteria producing a variety of \u03b2-lactamases. In this systematic review, we aimed to evaluate the available data on resistance to this drug. We performed a thorough search of four databases (Embase, PubMed, Scopus, and Web of Science), as well as backward citation searching, to identify studies containing data on resistance to cefepime-enmetazobactam. The data were extracted and analyzed according to the breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Food and Drug Administration (FDA), or the specific breakpoints reported by the authors of the respective studies. Analysis based on the type of lactamases produced by the isolates was also performed. Ten studies reported in vitro susceptibility testing and mechanisms of antimicrobial resistance. The total number of isolates was 15,408. The activity of cefepime-enmetazobactam against \u03b2-lactamase-producing isolates was variable. The resistance of the studied extended-spectrum \u03b2-lactamase (ESBL)-producing and ampicillin C \u03b2-lactamase (AmpC)-producing isolates was low (0\u20132.8% and 0%, respectively). The resistance was higher among oxacillinase-48 \u03b2-lactamase (OXA-48)-producing and Klebsiella pneumoniae carbapenemase (KPC)-producing isolates (3.4\u201313.2% and 36.7\u201357.8%, respectively). High resistance was noted among metallo-\u03b2-lactamase (MBL)-producing isolates (reaching 87.5% in one study), especially those producing New Delhi metallo-\u03b2-lactamase (NDM) and Verona integron-encoded metallo-\u03b2-lactamase (VIM), which had the highest rates of resistance. The high activity of cefepime-enmetazobactam against Enterobacterales and selected lactose non-fermenting Gram-negative pathogens, including ESBL-producing and AmpC-producing isolates, makes it a potential carbapenem-sparing agent. The drug should be used after in vitro antimicrobial susceptibility testing in patients with infections caused by OXA-48, KPC, and MBL-producing isolates.<\/jats:p>","DOI":"10.3390\/pathogens14080777","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T10:13:51Z","timestamp":1754475231000},"page":"777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, 151 23 Athens, Greece"},{"name":"School of Medicine, European University Cyprus, 6 Diogenous Str., 2404 Nicosia, Cyprus"},{"name":"Department of Medicine, Tufts University School of Medicine, 145 Harrison Ave, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura T.","family":"Romanos","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Kontogiannis","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Tsiara","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos A.","family":"Kakoullis","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, 6 Diogenous Str., 2404 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","article-title":"The latest advances in \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections","volume":"20","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_2","first-page":"83","article-title":"Pharmacokinetics of beta-lactam antibiotics","volume":"42","author":"Bergan","year":"1984","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sargianou, M., Stathopoulos, P., Vrysis, C., Tzvetanova, I.D., and Falagas, M.E. (2025). New \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics. Pathogens, 14.","DOI":"10.3390\/pathogens14040307"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/17460913.2025.2468112","article-title":"Cefepime-enmetazobactam: First approved cefepime-\u03b2- lactamase inhibitor combination for multi-drug resistant Enterobacterales","volume":"20","author":"Bhowmick","year":"2025","journal-title":"Future Microbiol."},{"key":"ref_5","unstructured":"U.S. Food and Drug Administration Exblifep\u00ae (2025, July 11). (Cefepime and Enmetazobactam) for Injection, for Intravenous Use: Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216165s000lbl.pdf."},{"key":"ref_6","unstructured":"(2025, July 11). Exblifep European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exblifep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Johnson, A., McEntee, L., Farrington, N., Kolamunnage-Dona, R., Franzoni, S., Vezzelli, A., Massimiliano, M., Knechtle, P., Belley, A., and Dane, A. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-\u03b2-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00180-20"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e01468-20","DOI":"10.1128\/AAC.01468-20","article-title":"Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia","volume":"65","author":"Das","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17425255.2024.2427310","article-title":"Cefepime\/Enmetazobactam: A microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation","volume":"21","author":"Darlow","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_10","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2024). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [34th ed.]. Report No.: \u039c100."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2021.02.031","article-title":"Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016\u20132018 from USA and Europe: Genotypic analysis of \u03b2-lactamases and comparative in vitro activity of cefepime\/enmetazobactam","volume":"25","author":"Belley","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","unstructured":"Carlos V\u00e1zquez-Ucha, J., Lasarte-Monterrubio, C., Guijarro-S\u00e1nchez, P., Ovia\u00f1o, M., \u00c1lvarez-Fraga, L., Alonso-Garc\u00eda, I., Arca-Su\u00e1rez, J., Bou, G., Beceiro, A., and Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a La Corogne (2025, July 10). Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel b-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam Against a Multicenter Collection of Carbapenemase-Producing Enterobacterales. Available online: https:\/\/agris.fao.org\/search\/en\/providers\/122439\/records\/67dad517677d8be0233bfede."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/jac\/dkaf051","article-title":"Comparative evaluation of disc diffusion and LiofilchemTM MTS strip methods with broth microdilution for cefepime\/enmetazobactam susceptibility testing","volume":"80","author":"Emeraud","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","first-page":"466","article-title":"Management of clinical infections of Escherichia coli by new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"14","author":"Kadry","year":"2022","journal-title":"Iran. J. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106377","DOI":"10.1016\/j.ijantimicag.2021.106377","article-title":"In-vitro activity of cefiderocol, cefepime\/zidebactam, cefepime\/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017\u20132020","volume":"58","author":"Lee","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jmii.2021.08.012","article-title":"In vitro activity of cefiderocol, cefepime\/enmetazobactam, cefepime\/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018\u20132020","volume":"55","author":"Liu","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgar.2024.04.014","article-title":"Evaluation of the activity of cefepime\/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates","volume":"38","author":"Morrissey","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Morrissey, I., Magnet, S., Hawser, S., Shapiro, S., and Knechtle, P. (2019). In vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014\u20132015. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00514-19"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105925","DOI":"10.1016\/j.ijantimicag.2020.105925","article-title":"In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae","volume":"56","author":"Tselepis","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Vasquez-Ponce, F., Dantas, K., Becerra, J., Melocco, G., Esposito, F., Cardoso, B., Rodrigues, L., Lima, K., de Lima, A.V., and Sellera, F.P. (2022). Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.01159-22"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Falagas, M.E., Kontogiannis, D.S., Zidrou, M., Filippou, C., and Tansarli, G.S. (2025). Global Epidemiology and Antimicrobial Resistance of Metallo-\u03b2-Lactamase (MBL)-Producing Acinetobacter Clinical Isolates: A Systematic Review. Pathogens, 14.","DOI":"10.3390\/pathogens14060557"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2117310119","DOI":"10.1073\/pnas.2117310119","article-title":"Studies on enmetazobactam clarify mechanisms of widely used \u03b2-lactamase inhibitors","volume":"119","author":"Lang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e00078-20","DOI":"10.1128\/AAC.00078-20","article-title":"Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model","volume":"64","author":"Bernhard","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Karaiskos, I., and Giamarellou, H. (2020). Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics, 9.","DOI":"10.3390\/antibiotics9020061"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam\u2013avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): A descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): A randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results from a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): A randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2217\/fmb.13.31","article-title":"Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: A prospective study","volume":"8","author":"Sahni","year":"2013","journal-title":"Future Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Katsarou, A., Stathopoulos, P., Tzvetanova, I.D., Asimotou, C.-M., and Falagas, M.E. (2025). \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics Under Development. Pathogens, 14.","DOI":"10.3390\/pathogens14020168"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.medj.2024.03.011","article-title":"Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?","volume":"5","author":"Bassetti","year":"2024","journal-title":"Med"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Roach, E.J., Uehara, T., Daigle, D.M., Six, D.A., and Khursigara, C.M. (2021). The Next-Generation \u03b2-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli. Microbiol. Spectr., 9.","DOI":"10.1128\/Spectrum.00918-21"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Moya, B., Barcelo, I.M., Bhagwat, S., Patel, M., Bou, G., Papp-Wallace, K.M., Bonomo, R.A., and Oliver, A. (2017). WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent \u201c\u03b2-Lactam Enhancer\u201d Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-\u03b2-Lactamase-Producing High-Risk Clones. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02529-16"},{"key":"ref_39","unstructured":"Wockhardt (2025, July 17). A Phase 3, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04979806."},{"key":"ref_40","first-page":"32443","article-title":"Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials","volume":"25","author":"Romanos","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"ref_42","unstructured":"Allecra (2025, July 11). A Phase 1, Open-Label, Single-Dose Study to Assess the Mass Balance, Pharmacokinetics and Metabolism of Intravenously Administered 14C-AAI101 in Healthy Male Subjects, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03775668."},{"key":"ref_43","unstructured":"Allecra (2025, July 10). Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AAI101 With Cefepime in Subjects With Varying Degrees of Renal Function, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03680352."},{"key":"ref_44","unstructured":"Allecra (2025, July 11). A Phase I Open-Label, Single-Centre Study to Assess the Concentration of AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03680378."},{"key":"ref_45","unstructured":"Allecra (2025, July 10). Phase I, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of AAI101 Administered Intravenously Alone or in Combination With Piperacillin or Cefepime to Healthy Adult Subjects, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03685084."},{"key":"ref_46","unstructured":"Allecra (2025, July 10). Randomized, Double-Blind, Multi-Center Study of Cefepime\/AAI101 in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03680612."},{"key":"ref_47","unstructured":"Allecra (2025, July 10). Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV over 2 Hr in Male or Female Participants from Birth to Less Than 18 Years of Age Hospitalised with cUTI, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05826990."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Albac, S., Anzala, N., Chavanet, P., Dunkel, N., Quevedo, J., Santerre Henriksen, A., and Croisier, D. (2024). In vivo efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing Klebsiella pneumoniae. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.02345-24"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/8\/777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:24:13Z","timestamp":1760034253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/8\/777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["pathogens14080777"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14080777","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}